BETAAccess all features while we're in beta! Some features may become paid later.Got feedback? Reach us 👉

Loading IBRX charts…

Search ticker or company⌘K

IBRX

01Multicharts 02Comparables 03Price target

May we use analytics cookies to see how vpside is used, including anonymous session recordings? Accepting also loads the price chart, which sets its own cookies. Essential cookies are always on. Privacy

IBRX · ImmunityBio, Inc. fundamentals · vpside

vpside

⌘K

IBRXMarket cap $8.7B/Last filing 10-Q, Q2 FY26 · 4 Aug 2026/IBRXMarket cap $8.7B/Last filing 10-Q, Q2 FY26 · 4 Aug 2026/IBRXMarket cap $8.7B/Last filing 10-Q, Q2 FY26 · 4 Aug 2026/IBRXMarket cap $8.7B/Last filing 10-Q, Q2 FY26 · 4 Aug 2026/

Filings synced 13:22 · Prices: prior close 30 Oct

IBRX

ImmunityBio, Inc.

Nasdaq · Biological products, (no diagnostic substances) (SIC 2836) · FY ends 31 Dec

01Multicharts 02Comparables 03Price target

Add a metric37 metrics

Revenue, quarterly

$51M+93.9% year on year

$60M$40M$20M$0

vpside.com

Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26

Company filings · 10-Q filed 4 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

99.3%−0.3 pp year on year

100%99.8%99.5%99.3%

vpside.com

Q1 ’24Q3 ’24Q2 ’25Q4 ’25Q2 ’26

Company filings · 10-Q filed 4 Aug 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$76M−45.0% year on year

$300M$200M$100M$0

vpside.com

Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26

Company filings · 10-Q filed 4 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$288M

$200M$0−$200M−$400M−$600M

vpside.com

Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26

Company filings · 10-Q filed 4 Aug 2026 · TTM = last four quartersvpside.com

Chart 05 is empty

Chart 06 is empty

Fundamentals: company filings · Q4 = full year − nine months · TTM = last four quarters